Ovid takes a novel approach to gene therapy

A tough couple of years has not stopped the rare epilepsy specialist Ovid Therapeutics from investing in gene therapy, an area that has proven the kiss of death for many other companies. The group hopes that, in Gensaic, it has signed up a partner that could help it tap into the next big thing: gene therapy delivered via phages, viruses that infect bacteria.